Alogliptin
- Generic Name
- Alogliptin
- Brand Names
- Incresync, Kazano, Nesina, Oseni, Vipidia
- Drug Type
- Small Molecule
- Chemical Formula
- C18H21N5O2
- CAS Number
- 850649-61-5
- Unique Ingredient Identifier
- JHC049LO86
- Background
Alogliptin is a selective, orally-bioavailable inhibitor of enzymatic activity of dipeptidyl peptidase-4 (DPP-4). Chemically, alogliptin is prepared as a benzoate salt and exists predominantly as the R-enantiomer (>99%). It undergoes little or no chiral conversion in vivo to the (S)-enantiomer. FDA approved January 25, 2013.
- Indication
Indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
- Associated Conditions
- Type 2 Diabetes Mellitus
- Associated Therapies
- -
Long-term Study of Alogliptin as an Add-on to Rapid-Acting Insulin Secretagogues in Type 2 Diabetes
- Conditions
- Interventions
- First Posted Date
- 2011-10-20
- Last Posted Date
- 2014-04-21
- Lead Sponsor
- Takeda
- Target Recruit Count
- 67
- Registration Number
- NCT01456130
Pharmacokinetics and Pharmacodynamics Study of Alogliptin in Healthy Korean Participants
- First Posted Date
- 2011-07-12
- Last Posted Date
- 2013-03-22
- Lead Sponsor
- Takeda
- Target Recruit Count
- 48
- Registration Number
- NCT01391663
Effects of Alogliptin on Pancreatic Beta Cell Function
- Conditions
- Interventions
- First Posted Date
- 2011-02-24
- Last Posted Date
- 2011-02-24
- Lead Sponsor
- Aichi Gakuin University
- Target Recruit Count
- 80
- Registration Number
- NCT01303055
- Locations
- 🇯🇵
Diabetes Center, Yokkaichi Social Insurance Hospital, Yokkaichi, Mie, Japan
🇯🇵Dept. of Intern. Med., School of Dentistry, Aichi Gakuin University, Nagoya, Aichi, Japan
🇯🇵Diabetes Clinic, Okazaki East Hospital, Okazaki, Aichi, Japan
Efficacy and Safety of Alogliptin in Participants With Type 2 Diabetes
- Conditions
- Interventions
- First Posted Date
- 2011-02-03
- Last Posted Date
- 2013-03-22
- Lead Sponsor
- Takeda
- Target Recruit Count
- 506
- Registration Number
- NCT01289119
Long-term Safety Study of Alogliptin in Participants With Type 2 Diabetes in Japan
- First Posted Date
- 2010-12-20
- Last Posted Date
- 2012-02-03
- Lead Sponsor
- Takeda
- Target Recruit Count
- 438
- Registration Number
- NCT01263496
Efficacy and Safety of Alogliptin in Participants With Type 2 Diabetes in Japan
- Conditions
- Interventions
- First Posted Date
- 2010-12-20
- Last Posted Date
- 2012-02-03
- Lead Sponsor
- Takeda
- Target Recruit Count
- 480
- Registration Number
- NCT01263470
Efficacy and Safety of Alogliptin Plus Metformin in Patients With Type 2 Diabetes
- Conditions
- Interventions
- First Posted Date
- 2009-12-02
- Last Posted Date
- 2013-03-26
- Lead Sponsor
- Takeda
- Target Recruit Count
- 784
- Registration Number
- NCT01023581
Cardiovascular Outcomes Study of Alogliptin in Patients With Type 2 Diabetes and Acute Coronary Syndrome
- Conditions
- Interventions
- First Posted Date
- 2009-08-31
- Last Posted Date
- 2014-05-02
- Lead Sponsor
- Takeda
- Target Recruit Count
- 5380
- Registration Number
- NCT00968708
Pharmacokinetics, Pharmacodynamics, and Safety of Alogliptin in Children, Adolescents and Adults With Type 2 Diabetes Mellitus
- First Posted Date
- 2009-08-12
- Last Posted Date
- 2015-01-29
- Lead Sponsor
- Takeda
- Target Recruit Count
- 46
- Registration Number
- NCT00957268
Efficacy and Safety of Alogliptin Plus Metformin Compared to Glipizide Plus Metformin in Patients With Type 2 Diabetes Mellitus
- Conditions
- Interventions
- First Posted Date
- 2009-03-05
- Last Posted Date
- 2013-12-03
- Lead Sponsor
- Takeda
- Target Recruit Count
- 2639
- Registration Number
- NCT00856284
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.